Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Ongoing progress toward last patient enrolled in pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025...
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025 Aligned development strategy...
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations...
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
Ongoing pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) FDA feedback provides direction for the comparative interim analysis With aligned strategy, interim analysis data...
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in a platform presentation GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the...
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport, Inc. ("AMT") on track to close before year end Company...
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
Issues New Warrants to this Investment Group for Possible Additional Funding of Up to $3.47 Million (if exercised) GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to...
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
Live webcast presentation on Thursday, October 12th at 12:00 PM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through...